These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23886797)

  • 21. Defining the High-Risk Population for Mortality After Resection of Early Stage NSCLC.
    Husain ZA; Kim AW; Yu JB; Decker RH; Corso CD
    Clin Lung Cancer; 2015 Nov; 16(6):e183-7. PubMed ID: 25979646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic obstructive pulmonary disease and comorbidities' influence on mortality in non-small cell lung cancer patients.
    Media AS; Persson M; Tajhizi N; Weinreich UM
    Acta Oncol; 2019 Aug; 58(8):1102-1106. PubMed ID: 31092081
    [No Abstract]   [Full Text] [Related]  

  • 23. The impact of comorbidity upon determinants of outcome in patients with lung cancer.
    Grose D; Morrison DS; Devereux G; Jones R; Sharma D; Selby C; Docherty K; McIntosh D; Nicolson M; McMillan DC; Milroy R;
    Lung Cancer; 2015 Feb; 87(2):186-92. PubMed ID: 25498829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
    Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis.
    Rice SR; Molitoris JK; Vyfhuis MAL; Edelman MJ; Burrows WM; Feliciano J; Nichols EM; Suntharalingam M; Donahue J; Carr SR; Friedberg J; Badiyan S; Simone CB; Feigenberg SJ; Mohindra P
    Clin Lung Cancer; 2019 Jan; 20(1):e107-e114. PubMed ID: 30337268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China.
    Xing PY; Zhu YX; Wang L; Hui ZG; Liu SM; Ren JS; Zhang Y; Song Y; Liu CC; Huang YC; Liao XZ; Xing XJ; Wang DB; Yang L; Du LB; Liu YQ; Zhang YZ; Liu YY; Wei DH; Zhang K; Shi JF; Qiao YL; Chen WQ; Li JL; Dai M;
    Cancer Med; 2019 Jul; 8(8):4055-4069. PubMed ID: 31150167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
    Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK; Khuri FR; Ramalingam SS
    Clin Lung Cancer; 2017 May; 18(3):286-292. PubMed ID: 28043773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
    Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
    J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor.
    Irisa K; Masago K; Togashi Y; Fujita S; Hatachi Y; Fukuhara A; Sakamori Y; Kim YH; Mio T; Mishima M
    Med Oncol; 2012 Mar; 29(1):185-92. PubMed ID: 21136210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.
    Singh N; Singh PS; Aggarwal AN; Behera D
    Clin Lung Cancer; 2016 May; 17(3):205-213.e1. PubMed ID: 26589440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Socioeconomic position and surgery for early-stage non-small-cell lung cancer: A population-based study in Denmark.
    Kærgaard Starr L; Osler M; Steding-Jessen M; Lidegaard Frederiksen B; Jakobsen E; Østerlind K; Schüz J; Johansen C; Oksbjerg Dalton S
    Lung Cancer; 2013 Mar; 79(3):262-9. PubMed ID: 23276505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer.
    Dreyer J; Bremer M; Henkenberens C
    Radiat Oncol; 2018 Nov; 13(1):213. PubMed ID: 30390700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer.
    Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kunizaki M; Taniguchi D; Nagayasu T
    Eur J Cardiothorac Surg; 2015 Apr; 47(4):e140-5. PubMed ID: 25548132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients.
    Lim JU; Yeo CD; Rhee CK; Kang HS; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():929-938. PubMed ID: 31118602
    [No Abstract]   [Full Text] [Related]  

  • 35. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment.
    Grose D; Morrison DS; Devereux G; Jones R; Sharma D; Selby C; Docherty K; McIntosh D; Louden G; Nicolson M; McMillan DC; Milroy R;
    Postgrad Med J; 2014 Jun; 90(1064):305-10. PubMed ID: 24676985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
    BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC).
    Lam VK; Bentzen SM; Mohindra P; Nichols EM; Bhooshan N; Vyfhuis M; Scilla KA; Feigenberg SJ; Edelman MJ; Feliciano JL
    Lung Cancer; 2017 Feb; 104():52-57. PubMed ID: 28213000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.
    Colinet B; Jacot W; Bertrand D; Lacombe S; Bozonnat MC; Daurès JP; Pujol JL;
    Br J Cancer; 2005 Nov; 93(10):1098-105. PubMed ID: 16234816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.
    Yorio JT; Yan J; Xie Y; Gerber DE
    Clin Lung Cancer; 2012 Nov; 13(6):448-57. PubMed ID: 22512997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.